PharmTech Drug Digest 11.20
News|Articles|April 16, 2015

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-05-06-2015
  • Volume 11
  • Issue 5

Recipharm Invests in Sythonics

Recipharm makes a strategic investment in Synthonics and partners in development of novel compounds.

 

Recipharm announced on April 14, 2015 that it made an equity investment in Synthonics Inc., a specialty pharmaceutical company focused on the discovery, development and licensing of metal-coordinated pharmaceuticals, and purchased $2.0 million of preferred stock in the company.

A further $2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016. 

In addition, Synthonics and Recipharm have entered into a joint development agreement under which Synthonics gains access to Recipharm’s expertise in drug development, marketing, and manufacturing in exchange for a royalty payment on certain of Synthonics’ compounds.

Synthonics has developed a drug delivery technology for metal coordination of pharmaceutical APIs. In connection with its investment, Recipharm’s Carl-Johan Spak has joined Synthonics’ board of directors. 

Source: Recipharm

 


Related to this article

Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.